Advagene Biopharma Co., Ltd.

NT$20.80As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6709Healthcare
Country Taiwan
PE (Fwd) •••
TSR 8Y CAGR (2.63%)
Div yield —
ROE (33.48%)
Biotechnology
Beta (5Y) 0.66
PE TTM —
TSR TTM (35.98%)
Mkt cap NT$1.235B
ROIC (21.12%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$21
0.91%
(69.09%)
Hold 8|8|4|2|4
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.22
0.25
0.24
0.26
19.04%
35.90%
27.05%
24.67%
RevenueNT$M
63.30
63.62
66.01
67.46
4.08%
3.64%
6.55%
10.71%
Peers (US$37.48M)
Cap (US$)
PE
37.25M
—
Capital
TTM
5Y
10Y
Leveragex
2.306
(0.633)
(0.583)
EBIT/Intx
0.140
0.025
0.024
Own earn%
(104.25)
22.58
57.47
Sh yield%
28.94
15.38
18.59
Owners
Insiders/Inst%
9.42
67.83
Short interest%
2.06
SBC / revenue%
0.57
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
10–15
$1 testx
—
Incr. ROIC%
3